IsoRay reported the treatment of a brain tumor that had metastasized from esophageal cancer with the company's liquid Cesium-131, also called Cesitrex, which recently received FDA clearance for internal radiation therapy. The treatment used GliaSite radiation therapy Balloon Catheter System, which delivers a high dose of radiation to an area and minimizes radiation exposure to healthy brain tissue.
The stock was up 10.12% to $2.94 at 10:36 a.m. on Tuesday.
Must Read: Warren Buffett's 25 Favorite Stocks
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.